Menu
Oslo, Norway, 27 February 2026 – Reference is made to the long-term incentive program of Thor Medical ASA (the "Company") for leading employees.
A total of 5,641,666 employee share options have today been exercised, and the board of directors of the Company has consequently resolved to issue a total of 5,641,666 new shares.
The following primary insiders have exercised the following number options:
Notifications of the transaction in accordance with the Market Abuse Regulation article 19 are attached to this announcement.
4,041,666 rights to receive shares resulting from the exercise of options have been transferred to a third party and will be sold in the market as customary for share option exercises. The settlement amount for the options, in respect of the sale of shares and the cash consideration, will be finally determined on the basis of the average selling price of the shares obtained by the third party in the market. Upon completion of the sales, all primary insiders are utilising the after-tax gain from the option program to buy new shares.
Following completion of the share capital increase, the Company's share capital will be NOK 71,956,459.80 divided by 359,782,299 shares, each with a nominal value of NOK 0.20.
For further information please contact:
Mathias Nilsen Reierth,
Head of Communications and Corporate Affairs
+47 988 05 724
mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle emitters, from naturally occurring thorium. Its proprietary production process requires no irradiation or use of nuclear reactors, and provides reliable, environmentally friendly, cost-efficient supply of alpha-emitters for the radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visit www.thormedical.com.
This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Securities Trading Act.
